The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, X.
Right arrow Articles by Robbins, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, X.
Right arrow Articles by Robbins, P. F.

The Journal of Immunology, Vol 155, Issue 3 1343-1348, Copyright © 1995 by American Association of Immunologists

ARTICLES

Identification of a tyrosinase epitope recognized by HLA-A24- restricted, tumor-infiltrating lymphocytes

X Kang, Y Kawakami, M el-Gamil, R Wang, K Sakaguchi, JR Yannelli, E Appella, SA Rosenberg and PF Robbins
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

A number of Ags recognized by class I-restricted, melanoma-specific T cells have recently been identified. In this report we demonstrated that tumor-infiltrating lymphocytes (TIL) from melanoma patient 1413 recognize a tumor Ag, tyrosinase, in the context of HLA-A24. This Ag had previously been shown to be recognized by an HLA-A24-restricted TIL, TIL 888, as well as HLA-A2-restricted, melanoma-specific T cells isolated from two additional patients. The peptide epitope recognized by TIL 1413 was then identified through the use of sequential deletions of the tyrosinase cDNA, as well as through prediction of HLA-A24 binding peptides based on a previously identified motif. Two peptides, a 9-amino acid peptide (AFLPWHRLF) and an overlapping 10-amino acid peptide (AFLPWHRLFL) containing an additional leucine at the carboxyl terminus, were both recognized by TIL 1413. Anti-peptide-specific CTL could be induced by repeated stimulation of peripheral blood lymphocytes from melanoma patient 1413, and this CTL line specifically recognized both HLA-A24+ B cell lines pulsed with the peptide and HLA- A24+ tyrosinase+ melanoma cells. This peptide thus represents a reagent that may be used to generate melanoma-specific T cells for adoptive immunotherapy, as well as in peptide vaccines for HLA-A24+ melanoma patients.


This article has been cited by other articles:


Home page
 IOVSHome page
S. Sugita, H. Takase, C. Taguchi, Y. Imai, K. Kamoi, T. Kawaguchi, Y. Sugamoto, Y. Futagami, K. Itoh, and M. Mochizuki
Ocular Infiltrating CD4+ T Cells from Patients with Vogt-Koyanagi-Harada Disease Recognize Human Melanocyte Antigens.
Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2547 - 2554.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. R. Lindsey, L. Gritz, R. Sherry, A. Abati, P. A. Fetsch, L. C. Goldfeder, M. I. Gonzales, K. A. Zinnack, L. Rogers-Freezer, L. Haworth, et al.
Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma
Clin. Cancer Res., April 15, 2006; 12(8): 2526 - 2537.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M R Hussein, D A H Elsers, S A Fadel, and A-E M Omar
Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
J. Clin. Pathol., March 1, 2006; 59(3): 316 - 324.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
A. M. Thomas, L. M. Santarsiero, E. R. Lutz, T. D. Armstrong, Y.-C. Chen, L.-Q. Huang, D. A. Laheru, M. Goggins, R. H. Hruban, and E. M. Jaffee
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
J. Exp. Med., August 2, 2004; 200(3): 297 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Mitchell, J. Kan-Mitchell, P. R. Morrow, D. Darrah, V. E. Jones, and M. F. Mescher
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
Clin. Cancer Res., January 1, 2004; 10(1): 76 - 83.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. E. Touloukian, W. W. Leitner, R. E. Schnur, P. F. Robbins, Y. Li, S. Southwood, A. Sette, S. A. Rosenberg, and N. P. Restifo
Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1
J. Immunol., February 1, 2003; 170(3): 1579 - 1585.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Halaban, R. S. Patton, E. Cheng, S. Svedine, E. S. Trombetta, M. L. Wahl, S. Ariyan, and D. N. Hebert
Abnormal Acidification of Melanoma Cells Induces Tyrosinase Retention in the Early Secretory Pathway
J. Biol. Chem., April 19, 2002; 277(17): 14821 - 14828.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sosman, J. M. Unger, P.-Y. Liu, L. E. Flaherty, M. S. Park, R. A. Kempf, J. A. Thompson, P. I. Terasaki, and V. K. Sondak
Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome
J. Clin. Oncol., April 15, 2002; 20(8): 2067 - 2075.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell
Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope
J. Clin. Oncol., February 15, 2002; 20(4): 1075 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
D Jager, E Jager, and A Knuth
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer
J. Clin. Pathol., September 1, 2001; 54(9): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Nakao, S. Shichijo, T. Imaizumi, Y. Inoue, K. Matsunaga, A. Yamada, M. Kikuchi, N. Tsuda, K. Ohta, S. Takamori, et al.
Identification of a Gene Coding for a New Squamous Cell Carcinoma Antigen Recognized by the CTL
J. Immunol., March 1, 2000; 164(5): 2565 - 2574.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Suzuki, H. Sahara, Y. Okada, T. Yasoshima, Y. Hirohashi, Y. Nabeta, I. Hirai, T. Torigoe, S. Takahashi, A. Matsuura, et al.
Identification of Natural Antigenic Peptides of a Human Gastric Signet Ring Cell Carcinoma Recognized by HLA-A31-Restricted Cytotoxic T Lymphocytes
J. Immunol., September 1, 1999; 163(5): 2783 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Valmori, M. J. Pittet, C. Vonarbourg, D. Rimoldi, D. Lienard, D. Speiser, R. Dunbar, V. Cerundolo, J.-C. Cerottini, and P. Romero
Analysis of the Cytolytic T Lymphocyte Response of Melanoma Patients to the Naturally HLA-A*0201-associated Tyrosinase Peptide 368-376
Cancer Res., August 1, 1999; 59(16): 4050 - 4055.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. H. Butterfield, A. Koh, W. Meng, C. M. Vollmer, A. Ribas, V. Dissette, E. Lee, J. A. Glaspy, W. H. McBride, and J. S. Economou
Generation of Human T-cell Responses to an HLA-A2.1-restricted Peptide Epitope Derived from {{alpha}}-Fetoprotein
Cancer Res., July 1, 1999; 59(13): 3134 - 3142.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. R. Reynolds, E. Celis, A. Sette, R. Oratz, R. L. Shapiro, D. Johnston, M. Fotino, and J.-C. Bystryn
HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients
J. Immunol., December 15, 1998; 161(12): 6970 - 6976.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Kawakami, P. F. Robbins, X. Wang, J. P. Tupesis, M. R. Parkhurst, X. Kang, K. Sakaguchi, E. Appella, and S. A. Rosenberg
Identification of New Melanoma Epitopes on Melanosomal Proteins Recognized by Tumor Infiltrating T Lymphocytes Restricted by HLA-A1, -A2, and -A3 Alleles
J. Immunol., December 15, 1998; 161(12): 6985 - 6992.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Correale, K. Walmsley, S. Zaremba, M. Zhu, J. Schlom, and K. Y. Tsang
Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide
J. Immunol., September 15, 1998; 161(6): 3186 - 3194.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Bettinotti, C. J. Kim, K.-H. Lee, M. Roden, J. N. Cormier, M. Panelli, K. K. Parker, and F. M. Marincola
Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy
J. Immunol., July 15, 1998; 161(2): 877 - 889.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. Shichijo, M. Nakao, Y. Imai, H. Takasu, M. Kawamoto, F. Niiya, D. Yang, Y. Toh, H. Yamana, and K. Itoh
A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes
J. Exp. Med., February 2, 1998; 187(3): 277 - 288.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Osanto
Vaccine Trials for the Clinician: Prospects for Tumor Antigens
Oncologist, October 1, 1997; 2(5): 284 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Halaban, E. Cheng, Y. Zhang, G. Moellmann, D. Hanlon, M. Michalak, V. Setaluri, and D. N. Hebert
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells
PNAS, June 10, 1997; 94(12): 6210 - 6215.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Halaban, E. Cheng, S. Svedine, R. Aron, and D. N. Hebert
Proper Folding and Endoplasmic Reticulum to Golgi Transport of Tyrosinase Are Induced by Its Substrates, DOPA and Tyrosine
J. Biol. Chem., April 6, 2001; 276(15): 11933 - 11938.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Todo, R. L. Martuza, S. D. Rabkin, and P. A. Johnson
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
PNAS, May 22, 2001; 98(11): 6396 - 6401.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.